Can-Fite BioPharma (NYSE:CANF) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note released on Friday. The firm issued a sell rating on the stock.

A number of other research analysts also recently weighed in on CANF. D. Boral Capital reiterated a “buy” rating and set a $10.00 target price on shares of Can-Fite BioPharma in a report on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Can-Fite BioPharma in a report on Tuesday, November 12th.

Can-Fite BioPharma Price Performance

Shares of NYSE:CANF opened at $1.58 on Friday. Can-Fite BioPharma has a 1 year low of $1.29 and a 1 year high of $4.69. The stock’s 50-day moving average is $1.59 and its 200 day moving average is $1.91. The company has a market cap of $5.59 million, a PE ratio of -0.88 and a beta of 1.12.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. BNP Paribas Financial Markets purchased a new position in Can-Fite BioPharma Ltd. (NYSE:CANF) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned approximately 0.71% of Can-Fite BioPharma as of its most recent SEC filing. 21.00% of the stock is currently owned by hedge funds and other institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.